Provectus Biopharmaceuticals, Inc. PVCT
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | -- | 57.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | -- | 57.50K |
| Cost of Revenue | 121.60K | 324.30K | 248.90K | 323.20K | 872.40K |
| Gross Profit | -121.60K | -324.30K | -248.90K | -323.20K | -814.90K |
| SG&A Expenses | 737.40K | 923.60K | 761.20K | 831.10K | 860.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 859.00K | 1.25M | 1.02M | 1.17M | 1.73M |
| Operating Income | -859.00K | -1.25M | -1.02M | -1.17M | -1.68M |
| Income Before Tax | -988.70K | -1.30M | -1.17M | -1.32M | -1.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -988.70K | -1.30M | -1.17M | -1.32M | -1.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.20K | 10.50K | 2.80K | 12.30K | 37.70K |
| Net Income | -982.60K | -1.29M | -1.17M | -1.31M | -1.81M |
| EBIT | -859.00K | -1.25M | -1.02M | -1.17M | -1.68M |
| EBITDA | -858.50K | -1.25M | -1.02M | -1.17M | -1.68M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 420.28M | 420.28M | 420.28M | 420.28M | 420.28M |
| Average Diluted Shares Outstanding | 420.28M | 420.28M | 420.28M | 420.28M | 420.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |